Why cold chain requirements are not holding COVID-19 vaccines back
23
Despite the stringent storage conditions required for Pfizer and BioNTech’s COVID-19 vaccine, the need for a return to normal life has levelled the playing field for all candidate prophylactics against SARS-CoV-2.
With BNT162b2, the Pfizer and BioNTech COVID-19 vaccine, having gained regulatory approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA)
1 and the US Food and Drug Administration (FDA),
2 the world is now one step closer to ending the current pandemic. Now, the next stage for the companies will be to successfully distribute and deliver the vaccine.